Premium
Application of mesenchymal stem cells to enhance non‐union bone fracture healing
Author(s) -
Mousaei Ghasroldasht Mohammad,
Matin Maryam M.,
Kazemi Mehrjerdi Hossein,
NaderiMeshkin Hojjat,
Moradi Ali,
Rajabioun Masoud,
Alipour Faeze,
Ghasemi Samaneh,
Zare Mohammad,
Mirahmadi Mahdi,
Bidkhori Hamid Reza,
Bahrami Ahmad Reza
Publication year - 2019
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.36441
Subject(s) - mesenchymal stem cell , bone healing , materials science , cancellous bone , adipose tissue , biomedical engineering , pathology , medicine , surgery
ECM components include a number of osteoinductive and osteoconductive factors, which are involved in bone fracture healing. In this study, a combination of adipose derived mesenchymal stem cells (Ad‐MSCs), cancellous bone graft (CBG), and chitosan hydrogel (CHI) was applied to the non‐union bone fracture and healing effects were evaluated for the first time. After creation of animal models with non‐union fracture in rats, they were randomly classified into seven groups. Radiography at 0, 2, 4, and 8 weeks after surgery, indicated the positive effects of Ad‐MSCs + CBG + CHI and Ad‐MSCs + CBG in treatment of bone fractures as early as 2 weeks after the surgery. These data were confirmed with both biomechanical and histological studies. Gene expression analyses of Vegf and Bmp2 showed a positive effect of Ad‐MSCs on vascularization and osteogenic differentiation in all groups receiving Ad‐MSCs, as shown by real‐time PCR. Immunofluorescence analysis and RT‐PCR results indicated existence of human Ad‐MSCs in the fractured region 8 weeks post‐surgery. In conclusion, we suggest that application of Ad‐MSCs, CBG, and CHI, could be a suitable combination for osteoinduction and osteoconduction to improve non‐union bone fracture healing. Further investigations are required to determine the exact mechanisms involved in this process before moving to clinical studies. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 301–311, 2019.